Acute Mountain Sickness Clinical Trial
Official title:
Randomized Controlled Trial for Assessment of a Novel Non-Pharmacologic Intervention for Decrease in Altitude Illness
The study is examining if an over-the-counter device (Theravent) worn while sleeping can reduce acute mountain sickness upon awakening in a high altitude trekking population.
The specific aim of this study is to evaluate if an inexpensive and disposable end-expiratory
pressure device can prevent acute mountain sickness (AMS). AMS is a common disorder found in
25-75% of hikers and trekkers in N. America and Europe who expediently ascend high altitude
(>8,000 ft). This environmental malady is insidious in onset and prevention is necessary not
just to limit progression to severe or fatal disease, but also to limit physiologic
deterioration in those who seek enjoyment or employment at high altitudes. One of the
hallmarks of both healthy and sick individuals sleeping at high altitude is an oscillating
pattern of respiration marked by periods of hyperventilation alternating with apnea or
hypopnea. This distressing "periodic breathing" pattern leads to a feeling of suffocation,
prevents restful sleep, and the hypoxic events may well worsen ensuing AMS. Prior studies
have found positive end-expiratory pressure (PEEP) an effective non-pharmacologic method to
prevent nocturnal desaturations and decreasing both AMS incidence and severity.
Traditionally, PEEP devices are cumbersome and expensive, and while showing promising
efficacy, are limited by both cost and portability as a useful non-pharmacologic option for
AMS prophylaxis. The SLEEP-AID methodology is designed to prospectively enroll participants,
randomized in a double blind placebo-controlled fashion to either the intervention [Theravent
(Ventus Medical) which is single use, inexpensive, and very small] or a visually identical
"sham" placebo group, and gather physiologic data to accurately reflect sleep patterns of
high altitude travelers and objective as well as subjective outcomes of the intervention. The
benefit of this approach will be to provide definitive data in a large and diverse cross
section of a real hiking population that is generalizable to the majority of tens of millions
of hikers, climbers, and high altitude tourists in the United States, Europe, Asia, and South
America.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04111263 -
Gut-microbiota Targeted Nutritional Intervention for Gut Barrier Integrity at High Altitude
|
N/A | |
Completed |
NCT01536288 -
Can Rhodiola Crenulata Intake Improve Oxygen Saturation and Decrease the Incidence of Acute Mountain Sickness
|
Phase 2 | |
Completed |
NCT00326703 -
Effects of Aircraft Cabin Altitude on Passenger Comfort and Discomfort
|
N/A | |
Completed |
NCT06310642 -
Efficacy of Prophylactic Treatment of Oral Prochlorperazine for Acute Mountain Sickness
|
Phase 4 | |
Completed |
NCT03561675 -
Effect of Acetazolamide on Acute Mountain Sickness in Lowlanders Older Than 40 Years
|
Phase 4 | |
Completed |
NCT00559832 -
Prevention of Acute Mountain Sickness by Intermittent Hypoxia
|
N/A | |
Completed |
NCT01436383 -
Oxidative Stress in Hypobaric Hypoxia
|
N/A | |
Completed |
NCT00603122 -
Acclimatization Mechanisms During Ascent to 7500m
|
N/A | |
Completed |
NCT00664001 -
Anti-Oxidant Supplementation for the Prevention of Acute Mountain Sickness
|
Phase 3 | |
Completed |
NCT00627965 -
Randomized, Controlled Trial of Regular Sildenafil Citrate in the Prevention of Altitude Illness
|
Phase 4 | |
Not yet recruiting |
NCT06145113 -
The Effect of Continuous Positive Pressure Ventilation on Symptoms of Acute Mountain Sickness
|
N/A | |
Recruiting |
NCT05733338 -
The Effects of Intermittent Hypoxia on Acute Hypoxic Injury
|
N/A | |
Completed |
NCT01522326 -
Comparison of Metoclopramide and Ibuprofen for the Treatment of Acute Mountain Sickness
|
N/A | |
Recruiting |
NCT06393998 -
CO2 Supplement for Treatment of Acute Mountain Sickness
|
N/A | |
Completed |
NCT03270787 -
Study of Compound Danshen Dripping Pills to Treat Acute Mountain Sickness
|
Phase 1/Phase 2 | |
Completed |
NCT02811016 -
Inhaled Budesonide and Acute Mountain Sickness
|
Phase 1 | |
Recruiting |
NCT00886912 -
Training in Hypoxia to Prevent Acute Mountain Sickness
|
N/A | |
Terminated |
NCT03956472 -
Alternative Treatments in Acute Mountain Sickness
|
N/A | |
Recruiting |
NCT03621410 -
T89 in Prevention and Treatment of Acute Mountain Sickness (AMS) During Rapid Ascent
|
Phase 2 | |
Active, not recruiting |
NCT01565603 -
Sleep and Cerebral Responses to High Altitude
|
N/A |